Immunotherapy has received tremendous attention for tumor treatment, but the efficacy is greatly hindered by insufficient tumor‐infiltration of immune cells and immunosuppressive tumor microenvironment. The strategy that can efficiently activate cytotoxic T lymphocytes and inhibit negative immune regulators will greatly amplify immunotherapy outcome, which is however very rare. Herein, a new kind of semiconducting polymer (SP) nanoparticles is developed, featured with surface‐mimicking protein secondary structure (SPSS NPs) for self‐synergistic cancer immunotherapy by combining immunogenic cell death (ICD) and immune checkpoint blockade therapy. The SPs with excellent photodynamic property are synthesized by rational fluorination, which can massively induce ICD. Additionally, the peptide antagonists are introduced and self‐assembled into β‐sheet protein secondary structures on the photodynamic NP surface via preparation process optimization, which function as efficient lysosome‐targeting chimaeras (LYTACs) to mediate the degradation of programmed cell death ligand‐1 (PD‐L1) in lysosome. In vivo experiments demonstrate that SPSS NPs can not only elicit strong antitumor immunity to suppress both primary tumor and distant tumor, but also evoke long‐term immunological memory against tumor rechallenge. This work introduces a new kind of robust immunotherapy agents by combining well‐designed photosensitizer‐based ICD induction and protein secondary structures‐mediated LYTAC‐like multivalence PD‐L1 blockade, rendering great promise for synergistic immunotherapy.

Precision medicine requires highly sensitive and specific diagnostic strategies with high spatiotemporal resolution. Accurate detection and monitoring of endogenously generated biomarkers at the very early disease stage is of extensive importance for precise diagnosis and treatment. Aggregation-induced emission luminogens (AIEgens) have emerged as a new type of excellent optical agents, which show great promise for numerous biomedical applications. In this review, we highlight the recent advances of AIE-based probes for detecting reactive species (including reactive oxygen species (ROS), reactive nitrogen species (RNS), reactive sulfur species (RSS), and reactive carbonyl species (RCS)) and related biomedical applications. The molecular design strategies for increasing the sensitivity, tuning the response wavelength, and realizing afterglow imaging are summarized, and theranostic applications in reactive species-related major diseases such as cancer, inflammation, and vascular diseases are reviewed. The challenges and outlooks for the reactive species-activatable AIE systems for disease diagnostics and therapeutics are also discussed. This review aims to offer guidance for designing AIE-based specifically activatable optical agents for biomedical applications, as well as providing a comprehensive understanding about the structure–property application relationships. We hope it will inspire more interesting researches about reactive species-activatable probes and advance clinical translations.

Precision medicine calls for accurate diagnostic and therapeutic methods that could increase the disease sensing and treatment outcome. The second near-infrared (NIR-II, 1000-1700 nm) window has attracted considerable attention as...

Lung cancer is one of the most diagnosed cancers and is the leading cause of cancer death. Photodynamic therapy (PDT) has been considered as a promising strategy due to its strong efficacy and negligible side effects. The development of potent PDT agents with an excellent tumor targeting capability is highly desirable but still not satisfied. In this work, we report a highly efficacious organic nanoplatform based on an aggregation-induced emission luminogen (AIEgen) and biomimetic modification for precise phototheranostics of lung cancer. An AIEgen with strong light absorption ability and bright deep red/near-infrared emission is designed and synthesized that possesses both type I and type II PDT processes. The AIEgen is encapsulated into nanoparticles (NPs) and further camouflaged with a Lewis lung carcinoma cell membrane to build a biomimetic nanoplatform. Both in vitro and in vivo experiments indicate that the cancer-cell-biomimetic NPs could significantly increase the tumor cell targeting ability and sensitively delineate the tumor site. Moreover, the cell-membrane-camouflaged NPs also show excellent antitumor efficacy in lung-cancer-bearing mice. This work demonstrates that the integration of highly efficient AIEgen and biomimetic cell membranes is able to boost the phototheranostic efficacy, representing a promising strategy for precise cancer diagnosis and treatment.